Title  | Date  | Price |
|---|
Cancer Diagnostic Testing World Markets
| Apr 2008 |
£2,105 |
CD40 and CD40L (CD154) Agonists and Antagonists
Brief Report
| Apr 2008 |
£225 |
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
| Apr 2008 |
£2,075 |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
| Apr 2008 |
£2,105 |
Cancer Cell Therapy Markets
| Mar 2008 |
£2,075 |
U.S. Breast Cancer Therapeutics Markets
| Mar 2008 |
£3,605 |
The Worldwide Market for Cancer Diagnostics
3rd Edition
| Mar 2008 |
£2,400 |
Cardiac Toxicity
| Mar 2008 |
£1,495 |
Syk Kinase Inhibitors
Brief Report
| Feb 2008 |
£135 |
Cancer Therapies: Technologies and Global Markets
| Jan 2008 |
£2,915 |
The Cancer Market Outlook to 2012
| Jan 2008 |
£2,305 |
Death Receptors TRAIL-R1/2
Brief Report
| Jan 2008 |
£180 |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
| Jan 2008 |
£1,600 |
Stakeholder Opinions: Head and Neck Cancer
| Nov 2007 |
£2,280 |
Who's Developing What in New Cancer Drugs?
| Nov 2007 |
£495 |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
| Nov 2007 |
£1,790 |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
| Oct 2007 |
£9,140 |
Decoding Big Pharmas R&D Strategy in Oncology
| Sep 2007 |
£3,360 |
Cancer Vaccine Developments to 2013
| Sep 2007 |
£1,296 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
| Jul 2007 |
£2,525 |
Melanoma - Targeted Therapeutics
| Jul 2007 |
£1,425 |
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
| Jul 2007 |
£9,140 |
Stakeholder Opinions: Primary Brain Cancer
| Jul 2007 |
£2,280 |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
| Jul 2007 |
£1,495 |
China Anti-tumor Drugs Market Report
2007
| Jun 2007 |
£180 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
| Jun 2007 |
£2,525 |
Antibody Drug Target Atlas in Oncology
| Jun 2007 |
£1,790 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
| Jun 2007 |
£2,525 |
Analytical Tool - Leukemia Therapeutics & Competitive Insights
| May 2007 |
£2,835 |
Analytical Tool - Hematological Cancers
| May 2007 |
£5,440 |
Analytical Tool - Analysis of Cancer Immunotherapy
The World Guide
| May 2007 |
£4,525 |
Analytical Tool - Current & Future Lung Cancer Therapeutics
| May 2007 |
£2,835 |
Analytical Tool - Lymphoma Therapeutics & Competitive Insights
| May 2007 |
£2,835 |
Cancer Drug Discoveries
What the Future Holds
| May 2007 |
£2,995 |
Cancer Drug Discoveries: Prostate Cancer
| May 2007 |
£795 |
Targeted Therapeutics in Non-Small Cell Lung Cancer
| Apr 2007 |
£1,425 |
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
| Apr 2007 |
£1,370 |
Global Cancer Focus Company Directory
| Apr 2007 |
£1,425 |
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma
Limited R&D activity provides opportunity for early-phase pipeline drugs
| Mar 2007 |
£2,280 |
Breast Cancer
Therapeutic And Competitive Insights
| Feb 2007 |
£1,425 |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
| Feb 2007 |
£1,730 |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
| Feb 2007 |
£2,400 |
Pipeline Insight: Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
| Dec 2006 |
£6,855 |
Stakeholder Insight: Pricing and Reimbursement in Oncology
Do payers believe oncology drugs offer good value?
| Dec 2006 |
£6,855 |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
| Dec 2006 |
£2,280 |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
| Dec 2006 |
£4,730 |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
| Dec 2006 |
£1,600 |
Regulator Perceptions in Cancer
Evolving opinions about the oncology drug approval process
| Nov 2006 |
£1,140 |
Emerging Cancer Vaccine Market, The
2nd Edition
| Nov 2006 |
£2,105 |
Pipeline/Commercial Insight: Colorectal Cancer
Shaping the future dynamics of colorectal cancer management
| Oct 2006 |
£7,955 |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
| Oct 2006 |
£7,955 |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
| Oct 2006 |
£7,955 |
Emerging Opportunities in Cancer Nanomedicine
| Aug 2006 |
£995 |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
| Apr 2006 |
£1,900 |
Cancer Vaccines
Measuring Market Potential
| Oct 2004 |
£900 |
Immunomodulators in Cancer Therapy
Emerging Products and Markets
| Aug 2004 |
£2,105 |
Analytical Tool: Competitive Outlook on HCV
| Jul 2004 |
£1,370 |
first
previous
